array(3) { ["company_details"]=> array(13) { ["name"]=> string(13) "Pharming B.V." ["slug"]=> string(20) "00474-nl-pharming-bv" ["logo"]=> string(84) "https://images.businessradar.com/linkedin_logos/6f06b060-b806-43f2-addd-a605083bf776" ["description"]=> string(987) "Pharming is a global biopharmaceutical company that develops and commercializes innovative protein replacement therapies and precision medicines for rare diseases. They are committed to being a sustainable partner for all stakeholder groups, including patients, healthcare professionals, employees, and shareholders. Pharming is headquartered in Leiden, the Netherlands, with its U.S. headquarters in Warren, New Jersey. They are listed on the Amsterdam Euronext and Nasdaq exchanges. Their vision is to become the leading global rare disease company and their mission is to bring solutions to unserved rare disease patients through drug development and commercialization. They aim to transform their pipeline to include multiple commercialized products in multiple geographies and to expand their technology portfolio. The company culture at Pharming emphasizes teamwork, self-development, and results orientation. They participate in investor conferences and provide financial updates." ["address_street"]=> string(12) "Darwinweg 24" ["address_place"]=> string(6) "Leiden" ["address_region"]=> NULL ["founding_date"]=> NULL ["website_domain"]=> string(12) "pharming.com" ["website_url"]=> string(24) "https://www.pharming.com" ["industry_codes"]=> array(1) { [0]=> string(75) "Industrial and Commercial Machinery and Equipment, Not Elsewhere Classified" } ["employee_count"]=> NULL ["article_count"]=> int(54) } ["articles"]=> array(2) { [0]=> array(7) { ["title_en"]=> string(51) "Pharming expects EU to reject key drug, shares dive" ["snippet_en"]=> string(177) "Dutch biotechnology firm Pharming Group NV expects the European Medicines Agency to deny approval for its key drug Rhucin, it said on Thursday, sending its shares sharply down." ["url"]=> string(79) "https://www.reuters.com/article/sppage015-l20428674-oishe-idUKL2042867420080320" ["image_url"]=> string(78) "https://images.businessradar.com/articles/5af61f72-8490-4e7f-bb7e-809970a9d1d2" ["source"]=> string(11) "reuters.com" ["publication_date"]=> string(10) "2008-03-20" ["categories"]=> array(2) { [0]=> string(14) "Issuing Shares" [1]=> string(22) "EU Political Evolution" } } [1]=> array(7) { ["title_en"]=> string(45) "Refinancing of loan gives Pharming a big blow" ["snippet_en"]=> string(108) "The share price of the biotech company falls by 10% after announcing the issuance of a new convertible bond." ["url"]=> string(96) "https://fd.nl/financiele-markten/1513955/herfinanciering-van-lening-bezorgt-pharming-flinke-klap" ["image_url"]=> NULL ["source"]=> string(5) "fd.nl" ["publication_date"]=> NULL ["categories"]=> array(2) { [0]=> string(5) "Debts" [1]=> string(14) "Issuing Shares" } } } ["category_annotations"]=> array(28) { [0]=> array(2) { ["name"]=> string(12) "Stock Market" ["count"]=> int(12) } [1]=> array(2) { ["name"]=> string(24) "Quarterly/Annual Figures" ["count"]=> int(8) } [2]=> array(2) { ["name"]=> string(10) "Insolvency" ["count"]=> int(4) } [3]=> array(2) { ["name"]=> string(31) "Financial Update/Profit Warning" ["count"]=> int(4) } [4]=> array(2) { ["name"]=> string(21) "Competitive Behaviour" ["count"]=> int(3) } [5]=> array(2) { ["name"]=> string(15) "Market Movement" ["count"]=> int(3) } [6]=> array(2) { ["name"]=> string(9) "Investors" ["count"]=> int(2) } [7]=> array(2) { ["name"]=> string(21) "Financial Performance" ["count"]=> int(2) } [8]=> array(2) { ["name"]=> string(14) "Issuing Shares" ["count"]=> int(2) } [9]=> array(2) { ["name"]=> string(5) "Event" ["count"]=> int(1) } [10]=> array(2) { ["name"]=> string(10) "Executives" ["count"]=> int(1) } [11]=> array(2) { ["name"]=> string(18) "Expansion & Growth" ["count"]=> int(1) } [12]=> array(2) { ["name"]=> string(18) "General Investment" ["count"]=> int(1) } [13]=> array(2) { ["name"]=> string(24) "Government Interventions" ["count"]=> int(1) } [14]=> array(2) { ["name"]=> string(14) "Product Review" ["count"]=> int(1) } [15]=> array(2) { ["name"]=> string(5) "R & D" ["count"]=> int(1) } [16]=> array(2) { ["name"]=> string(21) "Shareholders Feedback" ["count"]=> int(1) } [17]=> array(2) { ["name"]=> string(24) "Stock Research & Ratings" ["count"]=> int(1) } [18]=> array(2) { ["name"]=> string(11) "Acquisition" ["count"]=> int(1) } [19]=> array(2) { ["name"]=> string(9) "Valuation" ["count"]=> int(1) } [20]=> array(2) { ["name"]=> string(5) "Award" ["count"]=> int(1) } [21]=> array(2) { ["name"]=> string(12) "Board Change" ["count"]=> int(1) } [22]=> array(2) { ["name"]=> string(25) "Business Model Resilience" ["count"]=> int(1) } [23]=> array(2) { ["name"]=> string(11) "Competition" ["count"]=> int(1) } [24]=> array(2) { ["name"]=> string(15) "Deals & Tenders" ["count"]=> int(1) } [25]=> array(2) { ["name"]=> string(5) "Debts" ["count"]=> int(1) } [26]=> array(2) { ["name"]=> string(19) "Economic Conditions" ["count"]=> int(1) } [27]=> array(2) { ["name"]=> string(7) "Economy" ["count"]=> int(1) } } } 00474-nl-pharming-bv